Non-medical Switching from Reference to Biosimilar Etanercept - No Evidence for Nocebo Effect – a Retrospective Analysis of Real-life Data

Uta Kiltz¹, Styliani Tsiami ¹, Xenofon Baraliakos ² and Jürgen Braun ³, ¹Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ³Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Adverse events, biosimilars, etanercept, nocebo effect and switching

Session Information

Date: Monday, November 11, 2019

Title: Health Services Research Poster II – ACR/ARP

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Real-world data about switching patients from originator product to a biosimilars are important to assess and to document the outcome of switches in clinical practice in order to confirm the low risk of major problems. It has been hypothesized that lack of efficacy and adverse drug events (ADEs) upon switching from reference biologics to biosimilar products are related to the nocebo effect [1]. To evaluate the effectiveness and safety of systematic non-medical switching from innovator etanercept (Enbrel®) to biosimilar etanercept (SB4 (Benepali®)) in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) in a real-life setting based on different information strategies before switching.

Methods: Data of all adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) who had received innovator etanercept and were switched in our specialized center from innovator to biosimilar etanercept for economic reasons were retrospectively analysed. Whether or not patients were informed about the switch was left to the discretion of the treating physician. Disease activity and function were regularly assessed, and any changes were recorded in two consecutive visits at week 12 and 24. The scores documented at week 12 week after switching were taken as primary outcome. AEs were documented.

Results: A total of 84 patients were included (44 RA, 25 axSpA and 15 PsA patients), 24 of which had received information about switching (28.5%). The scores at week 12 of both, disease activity and function, remained rather unchanged (Table 1). Whether patients had been informed about switching or not did not influence outcomes or AE. The retention rate of the biosimilar was 96.4% (n=81) at week 12 and 87.6% (n=71) at week 24 (Figure 1). While 7 patients were lost to follow-up, 6 patients discontinued due to inefficacy or AE, including one malignant melanoma. Overall, 18 AEs were reported in 10 patients (12%). In 3 patients (3.6%) who had 5 AEs in the first 12 weeks the innovator was successfully re-administered.

Conclusion: Systematic switch from innovator to biosimilar etanercept was not associated with changes in disease activity or function in all three indications within 12 weeks. This was independent of information on the switch transmitted to the patients.

Table_1

Table 1: Patient characteristics

Figure_2

Figure 1: Retention of biosimilar stratified for patients with and without information.

Disclosure: U. Kiltz, AbbVie, 2, 5, 8, ABBVIE, NOVARTIS, CHUGAI, JANSEN, MSD, UCB, 8, ABBVIE, NOVARTIS, LILLY,BIOCAD, GRUNENTHAL,UCB, 5, ABBVIE, NOVARTIS, PFIZER,BIOGEN, 2, Biocad, 2, 5, Biogen, 2, 5, Chugai, 2, 5, 8, Eli Lilly, 2, 5, Eli Lilly and Company, 5, Grünenthal, 2, 5, 8, Janssen, 8, Jasnssen, 2, 5, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, Roche, 2, 5, 8, UCB, 2, 5, 8; S. Tsiami, None; X. Baraliakos, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, BMS, 2, 5, 8, 9, Bristol-Myers Squibb, 2, 5, 8, Celgene, 2, 5, 8, 9, Chugai, 2, 5, 8, 9, Janssen, 2, 5, 8, 9, Lilly, 2, 8, 9, Merck, 2, 5, 8, MSD, 2, 5, 8, 9, Novartis, 2, 5, 8, 9, Novatis, 2, 5, 8, Pfizer, 2, 5, 8, 9, UCB, 2, 5, 8, 9, UCB Pharma, 2, 5, 8, Werfen, 2, 5, 8; J. Braun, Abbott, 2, 5, AbbVie, 2, 5, 6, 8, Amgen, 2, 5, 8, Baxter, 2, 5, 8, Biogen, 2, 8, 9, BMS, 2, 5, 8, Boehringer, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Celgene, 2, 3, 5, 8, Celltrion, 2, 5, 8, Centocor, 2, 5, 8, Chugai, 2, 5, 8, Eli Lilly and Company, 2, 5, 8, Hexal, 2, 5, 8, Janssen, 2, 5, 8, Johnson & Johnson, 2, 5, Medac, 2, 5, 8, MSD, 2, 5, MSD (Schering-Plough), 2, 5, 8, Mundipharma, 2, 5, 8, Mylan, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, Pfizer (Wyeth, Hospira), 2, 5, 8, Roche, 2, 5, 8, Sanofi-Aventis, 2, 5, 8, UCB Pharma, 2, 5, 8.

To cite this abstract in AMA style:

Kiltz U, Tsiami S, Baraliakos X, Braun J. Non-medical Switching from Reference to Biosimilar Etanercept – No Evidence for Nocebo Effect – a Retrospective Analysis of Real-life Data [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/non-medical-switching-from-reference-to-biosimilar-etanercept-no-evidence-for-nocebo-effect-a-retrospective-analysis-of-real-life-data/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/non-medical-switching-from-reference-to-biosimilar-etanercept-no-evidence-for-nocebo-effect-a-retrospective-analysis-of-real-life-data/